Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine is under clinical development by CanSino Biologics and currently in Phase III for Neisseria meningitidis Infections. According to GlobalData, Phase III drugs for Neisseria meningitidis Infections have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine overview
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine) (Menhycia) is a sterile liquid vaccine. It is formulated as lyophilized injection solution for intramuscular route of administration. Menhycia is indicated for the prevention of epidemics caused by group A, C, Y and W135 Neisseria meningitidis cerebrospinal meningitis.
It is under development for the treatment of Neisseria meningitidis infections for people aged 7-59 years old and 4 to 6 year-old Population.
CanSino Biologics overview
CanSino Biologics is a biopharmaceutical company that develops, manufactures and commercializes pneumococcal, polyvalent conjugate and adenovirus-based recombinant TB vaccines. The company is investigating Ad5-EBOV, an adenovirus type 5 vector, to treat Ebola virus, MCV2 and MCV4 vaccines for the prevention of Neisseria meningitidis bacteria. It is also evaluating DTcP vaccine against pertussis caused after primary vaccination in infants and children and PBPV, PCV13i vaccines, targeting pneumococcal diseases. CanSino Biologics utilizes Adenovirus-based viral vector vaccine, conjugation, formulation and protein structure design and recombinant technology to develop vaccines. The company works in partnership with MC Master University, National Research Council of Canada and Beijing Institute of Biotechnology. CanSino Biologics is headquartered in Tianjin, China.
For a complete picture of Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
